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Abstract
The forkhead, winged-helix transcription factor FOXP3 is preferentially expressed in T regulatory (Treg) cells and is critical for
their immunosuppressive function. Mutations that abolish FOXP3 function lead to systemic autoimmunity in mice and
humans. However, the manner by which FOXP3 recognizes cognate DNA elements is unclear. Here we identify an in vitro
optimized DNA sequence to assess FOXP3 DNA binding by electrophoretic mobility shift assay (EMSA). The optimized
sequence contains two tandem copies of a core DNA element resembling, but not identical to, the canonical forkhead (FKH)
binding element. The tandem nature of this optimized FOXP3-binding oligonucleotide suggests a requirement for
multimerization, and EMSA experiments confirm that both the DNA-binding FKH domain and an intact leucine-zipper
domain, which mediates homo-multimerization of FOXP3, are required for DNA binding. These results establish a practical
framework for understanding the molecular basis by which FOXP3 regulates gene transcription and programs Treg
suppressive function.
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Introduction
Forkhead box (FOX) transcription factors are a large and
functionally diverse family of transcription factors, with over 100
members in mammals (reviewed in [1]). Named after the forkhead
gene product in Drosophila melanogaster, the founding members of
the mammalian FOX family belong to the hepatic nuclear factor-3
(HNF3/FOXA) family, which regulate the development of
metabolic tissues such as the pancreas and liver [2,3]. Many
FOX transcription factors are tissue-specific regulators of
development (reviewed in [4]): hair formation and keratinocyte
differentiation are regulated by Foxn1 [5], cell growth and insulin
responsiveness by Foxo1 [6], craniopharyngeal development by
FOXE1 [4], speech and language patterning by FOXP2 [7], and
auditory function by Foxi1 [8]. Additionally, several FOX proteins
play key roles in the development, homeostasis and function of
immune cells (reviewed in [9]). Foxo1, Foxo3 and Foxp1 all
regulate B cell ontogeny, possibly through direct transcriptional
regulation of the Rag1/2 locus [10–13]. In T cells, genetic ablation
of either Foxj1 or Foxo3 precipitates a lymphoproliferative
phenotype associated with variable autoimmune pathology
[14,15], suggesting that these FOX proteins negatively regulate
T cell activation.
Foxp3 (denoted FOXP3 in humans) displays one of the more
striking functions of a FOX protein within the immune system.
FOXP3 is selectively expressed by a subset of CD4+ T cells,
known as T regulatory (Treg) cells, which suppress effector T cell
function in response to self or foreign antigens (reviewed in
[9,16,17]. FOXP3 is encoded on the X-chromosome, thus loss or
mutation of FOXP3 is not deleterious in females. However,
mutations within the FOXP3 gene in male infants are causally
linked to IPEX (immune dysregulation, polyendocrinopathy,
enteropathy, X-linked), a severe perinatal autoimmune syndrome
resulting from defects in Treg development and consequent
activation of conventional T cells with specificity for self-antigens
[18,19]. IPEX patients develop lymphadenopathy, splenomegaly,
hyper-IgE production, variable hyperglycemia and lymphocytic
infiltrates into the lung, skin, pancreas and liver [18–20]. The
autoimmune phenotype of IPEX patients is phenocopied in male
scurfy (Foxp3
sf) mice, which harbor a spontaneous mutation in the
Foxp3 gene [16,21,22]. Male mice in which Foxp3 is conditionally
deleted in T cells using Cre recombinase expressed under the
control of the CD4 promoter (CD4-Cre) develop a similar severe
autoimmune phenotype [23], as do adult mice in which Foxp3-
expressing Treg cells are acutely ablated [24]. These observations
have resulted in much focus on the transcriptional regulatory
function of FOXP3.
FOXP3 contains a large (,181 aa) amino-terminal region
required for transcriptional activation and repression, a central
C2H2 zinc-finger domain to which no specific function has yet
been ascribed, a leucine-zipper domain implicated in multimer
formation and suppressor function, and a C-terminal forkhead
(FKH) domain that mediates DNA-binding by FOX proteins
[9,16]. FOXP3 can associate with auxiliary transcription factors
such as NFAT, AML1/Runx1, IRF4 (not shown to physically
interact with Foxp3) and NF-kB to drive the transcription of
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have been largely observed via co-immunoprecipitation and
chromatin immunoprecipitation (ChIP) assays. ChIP assays can
localize transcription factor binding to relatively large (200–
500 bp) regions of DNA, and have proved useful in confirming or
revealing target promoters likely to be directly regulated by
FOXP3 and its transcriptional partners. Large-scale ‘ChIP-chip’
assays, in which DNA occupied by specific transcription factors is
immunoprecipitated and hybridized to genome-wide tiling arrays,
have been used to identify DNA elements likely to bind FOXP3 in
vivo, either alone or in complex with transcriptional partners
[29,30]. However, these analyses have yet to be confirmed by in
vitro assays that directly assess FOXP3:DNA-binding.
Using a systematic series of electrophoretic mobility shift assays
(EMSA), we have explored the basis for the sequence-specific
DNA-binding by FOXP3. We show that a fragment lacking the
first 181 amino acids of FOXP3 (Foxp3-DN) binds DNA far more
robustly than full-length FOXP3. Efficient DNA binding by this
fragment requires both the leucine zipper and FKH domains. The
preferred oligonucleotide defined by EMSA assays as a high-
affinity FOXP3-binding site contains two tandem FOXP elements,
which are similar to, but somewhat divergent from, the classic
forkhead-binding sites previously identified for HNF3/FOXA
proteins. Based on the tandem nature of optimal FOXP3 binding
sequences, together with the requirement for the leucine-zipper
motif for DNA binding, we propose that FOXP3 binds DNA with
high affinity as at least a dimer and that the N-terminal region has
an autoinhibitory effect. Collectively, these results lay the
foundation for understanding how FOXP3 controls the immuno-
suppressive transcriptional program of Treg cells.
Methods
Plasmids
cDNAs encoding full length mouse Foxp1A (generous gift of Dr.
Phil Tucker, University of Texas-Austin) or full length human
FOXP3, as well as truncated and/or mutated versions were cloned
into the expression vector pcDNA3.1(+). Point mutations/
deletions were generated in the constructs using the Quickchange
site-directed mutagenesis system (Strategene).
Electrophoretic Mobility Shift Assays
The following oligonucleotide sequences were used as probes in









A’ (29 bp): 59-CAAGGTA AACAAGACAACGTAAACAA-
GTC-39;
A’ (25 bp): 59-CAAGGTAAACAAGAGTAAACAAGTC-39;
A’ (35 bp): 59-CAAGGTAAACAAGACAACACG ATTGTA-
AACAAGTC-39.
Single-strandedoligonucleotidescontainingtheconsensusFoxp1/
FOXP3 binding sites were annealed with their complementary
strands and purified on 12% polyacrylamide gels for use as probes in
electrophoretic mobility-shift assays (EMSA). Probes were end-
labeled with c
32P-ATP using T4 polynucleotide kinase in accor-
dance with manufacturers’ instructions. In vitro-translated proteins
were generated using the TNT reticulocyte lysate system (Promega).
Binding reactions were performed at room temperature for 20
minutes using 5 mlo fin vitro-translated proteins and approximately
10,000–20,000 c.p.m. (,0.1–0.5 ng) of
32P-end labeled probes in
20 ml. The final concentration of components of the binding buffer
for all EMSA experiments were: 12 mM HEPES pH 7.5, 100 mM
NaCl, 1 mM DTT, 1 mM EDTA, 12% glycerol and 20 mg/ml
poly(dI)-poly(dC). DNA-protein complexes were separated from free
probe by electrophoresis in a 5% polyacrylamide, TBE gel
containing 1% glycerol. Dried gels were exposed to autoradiography
film between 1 hour to overnight at room temperature. Quantifi-
cation of band intensities were performed on autoradiograms from
1 hour exposures using the software ImageJ.
Western Blot
Equal quantities of in vitro-translated protein lysates were
resolved by SDS-polyacrylamide gel electrophoresis and trans-
ferred to nitrocellulose membranes (Whatman). Immunoblots
were performed using either a monoclonal antibody against HA
(for HA-tagged Foxp1), a monoclonal antibody 1G1 raised against
the FKH domain of Foxp1 (generously provided by Dr. Philip
Tucker) or a polyclonal rabbit antisera raised against full-length
human FOXP3 (generously provided by Dr. Steven Ziegler).
Antibodies were diluted in Tris-buffered saline containing 0.1%
Tween-20 and 3% non-fat dry milk. Secondary horseradish
peroxidase-conjugated goat anti-mouse or anti-rabbit secondary
antibodies (Sigma-Aldrich) were used to detect primary antibody
binding, followed by detection with an enhanced chemilumines-
cence (ECL) reagent (Perkin-Elmer).
Results
All FOX transcription factors share a common winged-helix
DNA-binding domain of approximately 100 amino acids known as
the forkhead (FKH) domain [1,4,9]. HNF3/FOXA proteins bind
as monomers to DNA elements with the consensus sequence 59–
ATAACT–39 [32,33]; however, primary sequence analyses of
their FKH domains, and hence their putative sequence specificity
for DNA, show a significant degree of divergence from the FKH
domains of other FOX proteins [1]. Indeed Foxp1A, a close
relative of FOXP3, was found to prefer modified FKH/FOX
DNA elements (59 TATTTg/aTg/aTT-39) or its complement, 59–
AAc/tAc/tAAATA-39) in a PCR-based site-selection assay from
which the ‘‘A’’ oligonucleotide containing the preferred Foxp1
binding site was derived [34].
We previously showed using a nonradioactive EMSA format – in
which DNA and protein reactants are present at micromolar rather
than nanomolar concentrations – that recombinant FOXP3-FKH
domain expressed in bacteria bound very weakly on its own to the
ARRE2 sequence from the mouse IL-2 promoter but formed a
cooperative complex with recombinant NFAT1 DNA-binding
domain on DNA [25]. Binding of the isolated FKH domain of
FOXP3 to the ARRE2 sequence or the A oligonucleotide (see
below) could not be detected in radioactive EMSA assays (data not
shown), suggesting that other regions in FOXP3 are required for
optimal DNA binding. To explore this possibility, we synthesized
murine full-length HA-tagged Foxp1A (referred to throughout as
Foxp1), human full-length FOXP3, or defined fragments of FOXP3
(Figure 1A), by in vitro-transcription/translation in reticulocyte
lysates.Tocompare the abilityoftheseproteinstobindDNAin vitro,
we used theA oligonucleotide (sequenceshown inFigure 1B), which
contains theFoxp1 consensussequence[34], asthestartingprobe in
radioactive EMSA. All proteins were robustly expressed (Figure 1B,
bottom). As expected, full-length Foxp1 bound strongly to the A
probe (Figure 1B, lane 2), but surprisingly, full-length FOXP3 did
FOXP3: DNA Binding
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aminoacidsofFOXP3,here designatedFOXP3-DN [25],boundto
the A probe, although more weakly than that observed for Foxp1
(Figure 1B, lane 4). Binding to the A probe was specific, as neither
Foxp1 nor FOXP3-DN bound to a labeled oligonucleotide from the
variable 1 region of the immunoglobulin promoter (V1P), which
contains a canonical FOX consensus sequence defined for the
HNF3/FOXA proteins (data not shown) [33]. FOXP3-DNw a s
thus used in subsequent experiments to define the DNA-binding
specificity of FOXP3.
The weak binding of FOXP3-DN to the A probe prompted us
to derive an optimized sequence for FOXP3 DNA binding.
Sequence inspection of the A probe revealed two potential FOXP-
binding elements separated by a 7-nt spacer (Figure 2A). The 59
element (59–GTAAACA-39, here designated A1) matched a
computationally-identified FOXP3 binding element obtained via
ChIP-chip experiments (G/A T/c AAACA, Figure 2A) [30]. The
39 binding site (59–AACACAAATA, here designated A2) was
previously defined as the Foxp1 consensus site (59-AA C/t A C/t
AAATA, Figure 2A) [34]. FOXP3-DN contains a leucine-zipper
domain reported to mediate homotypic interactions, that is
mutated in a subset of IPEX patients [9,16], suggesting that the
A1 and A2 sequences might interact independently with FOXP3
forkhead domains within a FOXP3 multimer. To test this
hypothesis and determine whether FOXP proteins discriminated
between these sites, we synthesized two new double-stranded
oligonucleotides, A9 or A0, containing two A1 or A2 elements,
respectively (Figure 2A), and assessed their binding to in vitro-
translated Foxp1, Foxp1-DN, FOXP3, or FOXP3-DN proteins in
radioactive EMSA assays. For both Foxp1 and FOXP3, the DN
versions bound DNA more effectively than the full-length proteins
(Figure 2B), even though they were not over-expressed relative to
the full-length proteins (Figure 2C). In fact, DNA binding by full-
length FOXP3 was not detectable with any of the three probes
(Figure 2B). Both Foxp1-DN and FOXP3-DN displayed dimin-
ished binding to the A0 (A2-A2) probe but enhanced binding to the
A9 (A1-A1) probe, giving an order of preference for both proteins
of A9 (A1-A1) . A (A1-A2) . A0 (A2-A2) (Figure 2B).
Figure 1. Deletion of the FOXP3 N-terminal region allows binding to a Foxp1-like DNA element. (A) Fragments of human FOXP3
translated in vitro (see materials) for use in EMSA assays. Residue numbering is listed above full-length FOXP3. N-term – the N-terminal region (1–181)
of FOXP3, ZF – zinc finger, Zip – leucine zipper, FKH – forkhead domain. (B) Top – Full-length Foxp1 or FOXP3 fragments were expressed and
incubated with radiolabelled A probe. Arrowheads indicate Protein:DNA complexes and free probe. Bottom – Anti-HA monoclonal antibodies or
FOXP3 antiserum were used to detect expression of Foxp1 or FOXP3 fragments, respectively, by western blotting. Arrowheads indicate the position
of each construct. Data are representative of at least 2 independent experiments.
doi:10.1371/journal.pone.0008109.g001
FOXP3: DNA Binding
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8109Figure 2. DNA binding specificities of Foxp1 and FOXP3. (A) Sequences of the A probe [34], A9 and A0 oligonucleotides used for EMSA
experiments. The 59 putative FOXP3-binding site (A1) is similar to a predicted Foxp3 binding site [29,30] (see insert adapted from [30] below
sequence text). The 39 binding site (A2) represents the Foxp1 consensus site (blue text) as determined previously [34]. A9 has two putative FOXP3-
binding sites (A1-A1). A0 has two putative Foxp1 sites (A2-A2). (B) In vitro-translated firefly luciferase (Luc), Foxp1 (full-length or DN) or FOXP3 (full-
length or DN) were incubated with each labeled probe as indicated. Protein:DNA complexes and free probe are indicated at left (by arrowhead in one
case and a square bracket in the other). NS – non-specific. Quantification values of bound probe (shown as % bound of total detected probe in each
lane) were indicated below the lanes. (D) Expression of Foxp1 or FOXP3 constructs was evaluated by western blotting using anti-Foxp1 monoclonal
or anti-FOXP3 polyclonal antisera respectively. Loading amounts of in vitro-translated lysates were 4 ml for Luc and 1 ml, 2 ml and 4 ml for the Foxp1
and FOXP3 constructs as in (C). Data are representative of at least two independent experiments.
doi:10.1371/journal.pone.0008109.g002
FOXP3: DNA Binding
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probe,despitebindingtoA9(A1-A1)andA(A1-A2),suggeststhatthe
A1 sequence (GTAAACA) is essential for FOXP3 DNA binding.
The diminished binding of full-length Foxp1 and Foxp1-DNt oA 0
(A2-A2) was surprising, given that the probe contains the defined
Foxp1 consensus element [34] duplicated in tandem. These results
suggest thatthestrongbinding ofFoxp1 to the A oligonucleotide was
in fact facilitated by the presence of the A1 element (GTAAACA)
serving as a stronger Foxp1 consensus site than A2 (ACAAATA).
Since the A1 sequence (GTAAACA) is only one of four possible
sequences derived from the computationally-identified FOXP3
consensus site (G/A T/c AAACA) [30], we repeated the EMSA
assays using A9 (A1-A1) oligonucleotide probes that contained all the
possible combinations of these preferred nucleotides: AT, AC, GT
and GC (Figure 3A). FOXP3-DN showed a strong preference for
duplicated GTAAACA sequences, with binding affinity more than
doubled compared to the original A probe containing only one copy
of GTAAACA, or the oligonucleotide containing two ATAAACA
Figure 3. Definition of the FOXP3 consensus binding site. (A) Left – Using the A9 oligonucleotide sequence as a reference, the two 59
nucleotides were randomized within each of the two putative FOXP3 binding sites. Each FOXP3 binding site is underlined and the randomized 59
dinucleotide motifs are indicated by red text. Right – Computationally-determined putative FOXP3 binding site as in the figure 2 legend. (B) In vitro-
translated firefly luciferase (Luc), full-length FOXP3 or FOXP3-DN were incubated with each labeled probe as indicated. Protein:DNA complexes and
free probe are indicated by arrowhead and square brackets as in the legend to Figure 2. (C) The same experiment as described above in Figure 3B
was performed with in vitro-translated full-length Foxp1 or Foxp1-DN. Quantification values of bound probe were indicated below the lanes. These
data represent at least 2 independent experiments.
doi:10.1371/journal.pone.0008109.g003
FOXP3: DNA Binding
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sequences was further decreased, and binding was altogether
abolished to GCAAACA sequences (Figure 3B). These data suggest
that FOXP3-DN:DNA-binding is tightly regulated by the two 59
nucleotideswithinitsbindingsitesandgivesanorderofpreferenceof
GT.AT.AC (Figure 3B). Foxp1 displayed similar preferences for
its DNA-binding sites (Fig. 3C). In this case, however, the differential
preference for GT, AT and AC was less pronounced, whereas
binding to sequence starting with GC was again very weak.
Collectively, these experiments define the core consensus binding
element for both FOXP proteins as two tandem copies of the
sequence 59–GTAAACA–39.
We next asked whether the spacing between the two core
binding sites was important for FOXP3:DNA binding. For this we
used synthetic oligonucleotides in which the 59 ends of the two
FOXP3 consensus elements were separated by 14 base-pairs (bp),
as in the original A probe, or alternatively by 10 or 20 bp,
corresponding to one or two complete turns of the DNA helix
respectively, which would place the two sites on the same side of
the DNA (Figure 4A). We found that shortening the spacer length
between the two binding sites to 10 nucleotides, or lengthening the
spacing to 20 nucleotides, increased FOXP3-DN DNA binding by
,3-fold (Figure 4B). In contrast, Foxp1-DN preferred the longer
spacing, with the 20-bp spacing somewhat preferred over the 14-
bp spacing originally selected by PCR-based site selection
approaches (Figure 4B), but showed lower binding when the core
sites were spaced by 10 bp. These data suggest that the optimal
FOXP3 binding element contains two 59–GTAAACA–39 sites
Figure 4. FOXP3:DNA binding is regulated by spacing between tandem elements. (A) Sequences of the oligonucleotides used as probes in
EMSA assays. Each FOXP3 binding site is underlined with the first two nucleotides of each site highlighted in red text. The space (in number of
nucleotides) separating the 59 ends of the two binding sites is indicated below each sequence. The total number of base pairs in each sequence is
listed next to the probe name in parentheses. (B) In vitro-translated firefly luciferase (Luc), or FOXP3-DN were incubated with each labeled probe as
indicated. Protein:DNA complexes and free probe are indicated. Quantification values of bound probe were indicated below the lanes. All data shown
are representative of at least 2 separate experiments.
doi:10.1371/journal.pone.0008109.g004
FOXP3: DNA Binding
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be as close as 10 bp apart. However, the structural requirements
for binding differ from those of Foxp1, which seems to prefer
binding sites spaced apart by more than a single helical turn.
The fact that full-length FOXP3 did not bind even to the
optimized A9 (A1-A1) probe suggested that the N-terminal region
of FOXP3 has an autoinhibitory function that restricts DNA
binding in vitro. To define the boundaries of this putative region, we
in vitro-translated a series of FOXP3 proteins that all retained the
zinc-finger, leucine-zipper and FKH domains, but in which the N-
terminus was truncated to varying extents (Figure 5A, 5B-bottom).
No binding could be detected even to the spacing-optimized A9
(A1-A1)probe until the N-terminal121 aminoacids ofFOXP3 were
deleted. Truncation of the entire proline-rich N-terminus region
until amino acid 181, giving rise to FOXP3-DN, was required for
strongest binding to the probe (Figure 5B, lanes 6, 7).
In addition to the DNA-binding FKH domain, FOXP3-DN
contains a zinc-finger of unknown function and a leucine-zipper
domain reportedly involved in homo-multimerization (Figure 5C)
[9,16,35]. As expected, deletion of the FKH domain eliminated
DNA-binding by FOXP3-DN (Figure 5D, lane 1). Additionally,
FOXP3-DN:DNA binding was abrogated by two IPEX mutations
that affect the leucine-zipper domain (del K250 and del E251)
[16,35,36] (Figure 5D, lanes 2, 3). These single amino acid
deletions have been shown to abrogate FOXP3 multimerization
[35], presumably by affecting the positioning of leucine residues
along the face of the a-helical leucine-zipper domain. In contrast,
DNA binding of FOXP3-DN was not influenced by substitution of
a zinc-coordinating residue within the zinc-finger domain (C204S)
(Figure 5D, lane 4); nor was binding of FOXP3-DN enhanced by
including ZnSO4 in the binding reaction (data not shown). These
data indicate that the FKH domain and an intact leucine-zipper
are both required for optimal DNA-binding by FOXP3-DN,
whereas the zinc-finger domain is dispensable.
Discussion
FOXP3 prevents spontaneous autoimmunity by conferring on
Treg cells the transcriptional profile responsible for their immune-
suppressive activity. In this study we used a systematic series of
Figure 5. DNA binding by N-terminally truncated or point-mutated FOXP3. (A) Schematic representation of N-terminally truncated FOXP3
proteins used in EMSA assays. The position of the starting residue is listed next to each construct. (B) Top – Firefly luciferase (Luc), full-length FOXP3,
or FOXP3 N-terminal truncation mutants were in vitro-translated and incubated with labeled A9 (A1-A1) probe. Arrowheads indicate Protein:DNA
complexes. Bottom – expression of full-length FOXP3 or N-terminal FOXP3 mutants was determined by western blotting as in the legend to Figure 1.
(C) Diagram of the FOXP3-DN fragments used to determine the requirement of each domain for DNA binding. A single amino acid substitution within
the zinc-finger domain (C204S), or single amino acid deletions within the leucine-zipper domain (del K250, del E251) are indicated by red asterisks. (D)
Top – In vitro-translated firefly luciferase (Luc), or FOXP3-DN mutants were incubated with labeled A9 (A1-A1) probe. Arrowheads indicate Protein:DNA
complexes and free probe. Bottom – expression of FOXP3-DN mutant proteins was determined by western blotting. The same results were obtained
using the A9 (A1-A1) probe with 10-bp spacing described in Fig. 4. These data represent at least 2 independent experiments.
doi:10.1371/journal.pone.0008109.g005
FOXP3: DNA Binding
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interactions between FOXP3 and cognate DNA elements. We
show that the core FOXP3 consensus element contains the
sequence 59–(G/a)TAAACA–39; this sequence is also preferred by
the closely related transcription factor Foxp1, but diverges from
the classical FKH/FOX consensus site (59–ATAACT–39) defined
for the HNF3/FOXA proteins [32–34]. The consensus Foxp1/
FOXP3 binding element we have defined here is substantiated by
previous studies that identified Foxp3 binding sites throughout the
genome via ChIP-chip [29,30]. In these reports, the predicted
Foxp3 binding sequence was 59–(A/G)(T/C)AAACA–39. Our
analysis has further defined the sequence specificity of FOXP3 as
strongly preferring thymine at position 2 and favoring guanine at
position 1, although adenine is also tolerated.
The degenerate nature of FOXP3 binding sites in vivo [29,30]
may reflect the contributions of additional co-factors at specific
loci. This hypothesis is supported by previous work showing that
FOXP2 and FOXP3 can bind DNA at a non-consensus site in the
Il2 promoter (59-TGTTTCA-39) [25]. The complement of this
sequence, 59–TGAAACA–39, matches the FOXP3 binding
sequence defined here except for inversion of the order of the
first two nucleotides [25], which on its own would be predicted to
be non-permissive for FOXP3:DNA binding. However, this site is
located immediately adjacent to an NFAT site in the composite
ARRE-2 element that also binds NFAT:AP-1 complexes, and the
strong cooperative complexes formed between NFAT:AP-1 and
NFAT:FOXP3 at this composite element promote and inhibit Il2
gene transcription respectively [25]. Thus, although FOXP3
binding in vitro is restricted to its defined consensus site and
requires tandem binding elements, cooperative DNA binding by
FOXP3 in complex with other transcription factors may stabilize
FOXP3 binding at non-consensus sites [25,26,28].
Unlike the HNF3/FOXA proteins, which bind with high
affinity as monomers to single consensus sites [33], we show here
that Foxp1 and FOXP3 preferentially bind oligonucleotides
containing two consensus sites arrayed in tandem. These results
suggest that FOXP proteins bind DNA as at least a dimer [34]. In
further support of this hypothesis, we find that DNA binding by
FOXP3 requires the FKH domain together with an intact leucine-
zipper domain, whereas the zinc-finger domain is dispensable. The
leucine-zipper domain of FOXP3 mediates homotypic interactions
[35], whereas HNF3/FOXA proteins lack a leucine-zipper
[4,9,33]. Therefore, the presence of a leucine-zipper domain
within FOX proteins correlates with their distinctive preference for
tandem sequences in DNA. Indeed, at least two independent
single amino acid deletions within the leucine-zipper of FOXP3
(del K250, del E251), both associated with IPEX [16,36], fail to
bind our optimized DNA sequence in EMSA assays (Figure 5D).
Our data therefore suggest that the primary loss of function in
these IPEX mutants relates to dimerization and DNA binding.
Interestingly, FOXP3:DNA binding in vitro was only detected
upon removal of the N-terminal region (FOXP3-DN); truncating
the corresponding N-terminal region of Foxp1 also enhanced
DNA binding. A trivial possibility is that the N-terminal region is
unstructured and interferes, in the in vitro-translated protein, with
DNA binding or multimerization. Another, more interesting
possibility is that the N-terminal region of FOXP3 possesses an
autoinhibitory function, possibly regulating FOXP3:DNA binding
indirectly. Sequence comparisons between the N-terminal regions
of FOXP proteins indicate significant divergence (reviewed in [1]).
For example, the Foxp1 N-terminal region contains a poly-
glutamine (poly-Q) sequence that is absent from the N-terminus of
FOXP3 [34]. Furthermore, this N-terminal region of FOXP3 is
responsible for activation as well as repression of target genes
[25,35], and has been shown to interact with a number of auxiliary
transcription factors and chromatin-modifying proteins [39].
Thus, N-terminal sequence divergence among FOXP proteins
may serve to recruit unique protein complexes to target promoters,
which in turn would dictate whether gene transcription is activated
or repressed. Consistent with this notion, previous reports have
shown that FOXP3:DNA binding is increased, in a cyclosporine
A-sensitive manner, upon stimulation of T cells through the T cell
antigen receptor [25,30,40]. A plausible hypothesis is that the N-
terminal region of FOXP3 regulates DNA binding and transcrip-
tional activity, either through co-factors that bind this region or
through post-translational modification.
In summary, we have defined an optimal set of in vitro conditions
to study FOXP3:DNA binding: (1) by removing the proline-rich
N-terminal region of FOXP3, and (2) by using an optimized probe
containing two consensus sites, 59- GTAAACA-39 separated by
one or two turns of the DNA helix. Our findings will facilitate
further structural studies of FOXP3 in complex with DNA,
promoting a precise biochemical understanding of how FOXP3
binds to DNA, either alone or in cooperation with its
transcriptional partners, to regulate the expression of target genes
in Treg cells.
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